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Abstract: Metabolically unhealthy obesity (MUO) is a regular state in people with primary
hypertension (HTN), obesity, and who are physically inactive. To achieve and maintain a metabolically
healthy overweight/obese (MHO) state should be a main treatment goal. The aims of the study
were (1) to determine differences in metabolic profiles of overweight/obese, physically inactive
individuals with HTN following a 16-week (POST) supervised aerobic exercise training (SupExT)
intervention with an attentional control (AC) group, and (2) to determine whether the changes
observed were maintained following six months (6 M) of unsupervised time. Participants (n = 219)
were randomly assigned into AC or SupExT groups. All participants underwent a hypocaloric
diet. At POST, all participants received diet and physical activity advice for the following 6 M,
with no supervision. All measurements were assessed pre-intervention (PRE), POST, and after 6 M.
From PRE to POST, MUO participants became MHO with improved (p < 0.05) total cholesterol (TC,
∆ = −12.1 mg/dL), alanine aminotransferase (∆ = −8.3 U/L), glucose (∆ = −5.5 mg/dL), C-reactive
protein (∆ = −1.4 mg/dL), systolic blood pressure (SBP), and cardiorespiratory fitness (CRF) compared
to unhealthy optimal cut-off values. However, after 6 M, TC, glucose, and SBP returned to unhealthy
values (p < 0.05). In a non-physically active population with obesity and HTN, a 16-week SupExT
and diet intervention significantly improves cardiometabolic profile from MUO to MHO. However,
after 6 M of no supervision, participants returned to MUO. The findings of this study highlight the
need for regular, systematic, and supervised diet and exercise programs to avoid subsequent declines
in cardiometabolic health.
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1. Introduction
Obesity is a complex and chronic non-communicable disease with a disparity in the way it is
classified [1]. The combination of obesity, physical inactivity, and primary hypertension (HTN) is
widely recognized as a pre-eminent cause of cardiovascular risk and metabolic complications [2,3], and
is termed ‘metabolically unhealthy obesity’ (MUO) [4,5]. Therefore, to become metabolically healthy
overweight/obese (MHO) (i.e., overweight/obesity in the absence of a clearly defined cardiometabolic
disorder and/or high level of cardiorespiratory fitness (CRF)) [6,7] should be one of the main priorities
in the treatment of this population. A previous systematic review and meta-analysis found that MHO
individuals had significantly higher levels of physical activity and CRF, and spent less time in sedentary
behaviour than MUO, suggesting that a healthier metabolic profile could be partially due to a healthier
lifestyle [5].
Major international guidelines recommend non-pharmacological, tailored, and long-term
lifestyle changes for the prevention and treatment of HTN and obesity in this population [8–10].
Previously, interventions with engagement in regular physical activity, exercise, and a healthy diet in
overweight/obese individuals with HTN reported significantly reduced blood pressure (BP) [10,11],
and improved body composition [8,11], CRF [11,12], and biochemical profile [12,13]. In addition, it was
suggested that physical activity and diet recommendations were not enough to improve biochemical
profile alone and that supervision was needed [14]. As such, education programs (including healthy
diet and physical exercise) should be regular, systematic, and supervised by specialists. This is
particularly important since previously it has been found that declines in cardiometabolic health occur
after finishing a time-limited exercise program in different populations [15–17].
Previous data from the EXERDIET-HTA investigation found that all study groups improved body
composition, BP, and CRF following a 16-week intervention program [11]. However, there was a
significant reduction in the improvements found after the 6-month (6 M) follow up, when the exercise
and diet supervision were removed and only recommendations were applied [14]. Nevertheless,
no known study has analysed the changes in metabolic profile in an overweight/obese population
with HTN. Accordingly, the aims of the study were (1) to determine differences in metabolic profiles of
overweight/obese, physically inactive individuals with HTN following a 16-week supervised aerobic
exercise training (SupExT) intervention with an attentional control (AC) group, both with a hypocaloric
diet, and (2) to analyse whether the changes observed during supervision were maintained following
6 M of unsupervised time.
2. Methods
2.1. Research Design
The EXERDIET-HTA study is a randomised controlled trial (ClinicalTrials.gov ID: NCT02283047)
that compares the immediate (POST) and 6 M-effects of different 16-week SupExT programmes
(performed 2 days/week) combined with a dietary intervention in physically inactive, overweight/obese
individuals with HTN. The Clinical Investigation of Araba University Hospital (2015-030) and the
Ethics Committee of The University of the Basque Country (UPV/EHU, CEISH/279/2014) approved the
study design, protocols, and informed consent. More details regarding the design, selection criteria,
and procedures of the EXERDIET-HTA study have been explained in previous publications [11,14,18].
2.2. Participants
The EXERDIET-HTA study was conducted in Vitoria-Gasteiz (Basque Country, Spain).
Non-Hispanic white adult participants (n = 219) took part in the study, but 23 participants left the study
during the intervention and 19 participants did not attend the 6 M follow-up visit. These participants
did not differ in any way from the main sample. As such, 177 participants (n = 114 men and n = 63
women, 51.6 ± 8.9 years) were included in the analysis. Figure 1 represents the participants and design
of the EXERDIET-HTA study from recruitment to 6 M post intervention. The main inclusion criteria
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were being physically inactive and having overweight/obesity with primary HTN. The International
Physical Activity Questionnaire (IPAQ) determined physical activity behaviour [19], and participants
were below the “Global Recommendations on Physical Activity for Health” set by the World Health
Organization [20]. Body mass index (BMI) had to be above 25 kg·m2 [8]. Primary HTN was defined
as systolic BP (SBP) of 140–179 mmHg and/or diastolic BP (DBP) of 90–109 mmHg, and/or under
antihypertensive pharmacological treatment [21]. For all other inclusion and exclusion criteria, please
refer to the previously published study protocol [18].
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Figure 1. Flow di gram of the EXERDIET-HTA study from recruitment to the 6-month
unsupervised period.
In addition to the EXERDIET-HTA s udy participants, another group was created to allow for
comparison to a normal body mass healthy popul t on (hereinafter termed: HEALTHY). The HEALTHY
(n = 31, 40.0 ± 9.0 years, 58% women) group did not participate in any intervention. Only baseline
measures were assessed for comparison to the EXERDIET-HTA study participants. Inclusion for
HEALTHY criteria were age (25–55 years) and exclusion criteria were being pregnant, currently
breastfeeding, taking regular medication, or having any known medical condition.
2.3. Measurements
Anthropometric, clinical, and physiological measurements were taken at baseline (PRE),
immediately after the 16-week intervention (POST), and at 6 M follow-up (Figure 1) by trained
investigators and specialists. Each assessment included anthropometry (body mass, stature, BMI, waist
circumference, and body composition), 24 h ambulatory BP monitoring, determination of peak oxygen
uptake (
·
VO2peak) to asses CRF, and collection of fasting blood samples (12.5 mL) at the Clinical Trials Unit
of Tecnalia (HUA, Vitoria-Gasteiz). The fasting blood samples were used to determine the metabolic
profile which consisted of: C-reactive protein (CRP), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), gamma-glutamyl tra speptidase (GGT), total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein choleste ol (LDL-C), triglycerides (TG),
glucose, insulin, and haemoglobin A1c (HbA1c). HOmeostatic M d l Assessment-Insulin resis ance
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index (HOMA-IR) was determined by: fasting serum insulin (µU/mL) × fasting plasma glucose
(mg/dL)/405 [22]. For more details of the assessments, please refer to the study protocol [18] and
previous cardiometabolic profiling manuscript [14].
The cut-off points of parameters related to cardiometabolic abnormalities were: concentrations of
CRP > 3 mg/L [23]. Hepatic enzymes when AST > 30 U/L, ALT > 30 U/L, GGT > 50 U/L [24]. With
respect to the lipid profile, when TC > 200 mg/dL (52 mmol/L), LDL-C > 100 mg/dL (26 mmol/L),
HDL-C < 40 mg/dL (10.4 mmol/L), TG > 200 mg/dL (2.28 mmol/L), and TC/HDL-C ratio > 3.5 [25].
Based on the Diabetes Federation Statement [26], glucose > 100 mg/dL (5.55 mmol/L). The HOMA-IR
ratio cut point was established at 3.8, insulin cut point at 16.7 mU/L, and HbA1c at 6% [27,28]. A CRF
(
·
VO2max in mL·kg−1·min−1) reference value lower than the 50th percentile was used as the cut-off
point, according to the FRIEND Registry [29]. The definition of the MUO and the MHO phenotypes
were obtained based on the joint combination of obesity markers (i.e., BMI) and cardiometabolic
abnormalities, taking into account the following definitions: the National Cholesterol Education
Program-Adults Treatment Panel III, Wildman, Wildman Modified and Ortega [4,5,30].
2.4. Intervention and 6-Month Post-Intervention Follow-up
After baseline measurements, participants were randomly allocated into one of the intervention
groups stratified by sex, SBP, BMI, and age using a time-blocked computerised randomisation program.
All participants underwent a hypocaloric DASH diet (Dietary Approaches to Stop Hypertension) [13].
Habitual food consumption and nutrient intake were evaluated using three questionnaires: Dietary
History, Food Frequency Questionnaire, and 24 h Recall Questionnaire. Every 2 weeks, participants
were weighed and received encouragement and advice alongside nutritional counselling in order to
aid compliance. The four intervention groups were AC group (AC, participants were given physical
activity advice only), and three SupExT groups: high-volume and moderate-intensity continuous
training, high-volume and high-intensity interval training, and low-volume and high-intensity interval
training. These groups trained on 2 non-consecutive days under supervision by exercise specialists
for 16-weeks. The advice for the AC group was to participate in at least 30 min of moderate-intensity
aerobic exercise (walking, jogging, cycling, or swimming) for 5–7 days per week blended with some
dynamic resistance exercises [18].
In a preliminary analysis of the data used in this article, SupExT groups had no significant
differences (p > 0.05) among them in the target variables (biochemical profile variables) over time
(i.e., PRE versus POST, POST versus 6 M, and PRE versus 6 M). Therefore, for the purposes of this
article, the three SupExT groups were put together in one group and thus comparative analyses were
performed between groups (AC versus SupExT).
After POST assessment, all participants received physical activity and diet advice for the following
6 M. Participants had no further supervised intervention or attention from any of the research staff.
All participants received exercise intensity domains (i.e., individual heart rate values at moderate- and
high-intensity ranges) to self-monitor. All the protocols for each group, including procedures and diet
intervention, have been previously published [11,18].
2.5. Statistical Analysis
Descriptive statistics were calculated for all variables and presented as mean ± standard deviation
(SD) or percentage. To determine normality, a Kolmogorov–Smirnov test was performed on all variables,
and those with a skewed distribution were log-transformed prior to any analysis. For comparisons
between HEALTHY and the EXERDIET-HTA study population, independent t-tests were used to assess
mean differences for continuous variables, and the chi-square test was performed to verify frequency
differences for categorical variables. One-way repeated measures analysis of variance (ANOVA) was
used to test the change in biochemical profile variables over time, when the differences presented
significance, the Bonferroni post hoc test was applied. From the repeated measures ANOVA, partial
eta-squared (ηp2) was reported as a measure of effect size (ES). Two-way repeated measures ANOVA
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was used to evaluate the interaction effects (time × group) in biochemical profile variables. Analysis of
covariance (ANCOVA) was performed to test the differences between groups for the delta score (∆,
differences between PRE versus POST, POST versus 6 M follow-up, and PRE versus 6 M follow-up),
adjusting the analysis for age, sex, medication intake, and changes in body mass. Cochran’s Q test
was executed to analyse the change in medication intake and smoking status. Chi-square test was
used to test the differences between groups for the change in medication intake and smoking status
(differences between PRE versus POST, POST versus 6 M follow-up, and PRE versus 6 M follow-up)
over time. As previously described in the study protocol [18], the required sample size was determined
for the primary outcome variable (SBP) of the EXERDIET-HTA study. It was identified that adequate
power (0.95) to evaluate differences in our design consisting of four experimental groups would be
achieved with 164 people (41 each group, α = 0.05, ES f = 0.4). Data were analysed according to the
intention-to-treat principle. All statistical analyses were performed using the Statistical Package for
Social Science (SPSS) version 24.0 (IBM Corp., Armonk, NY, USA). For all analysis, the alpha level of
significance was set at p < 0.05.
3. Results
Table 1 presents baseline anthropometric, BP, CRF, biochemical profile, medication intake, and
smoking status data of the EXERDIET-HTA study population compared to the HEALTHY group.
The EXERDIET-HTA study population had significantly higher (p < 0.05) age, BM, BMI, waist
circumference, SBP, DBP, mean BP (MBP), CRP, AST, ALT, GGT, TC, LDL-C, TG, TC/HDL-C, glucose,
insulin, HOMA-IR, and HbA1C compared to the HEALTHY group. Nevertheless, the EXERDIET-HTA
group had significantly lower fat-free mass,
·
VO2peak, and HDL-C than the HEALTHY group. There was
no difference in smoking status between groups. As previously described [31], the participants from the
EXERDIET-HTA study were considered MUO with the following parameters showing concentrations
and values with cut-off points outside of those considered healthy: LDL-C, TC, TC/HDL-C, ALT,
glucose, BP, CRP, and low CRF.
Table 1. Baseline results of the study population compared to a HEALTHY (normal body mass healthy
population) group.
Variables
HEALTHY EXERDIET-HTA P
PHEALTHY-EXERDIET-HTA(n = 31) (n = 219)
Age (years) 40.0 ± 9.0 53.3 ± 7.6 <0.001
Body mass (kg) 66.1 ± 10.5 92.4 ± 15.1 <0.001
BMI (kg/m2) 22.7 ± 2.2 32.4 ± 4.2 <0.001
Waist circumference (cm) 74.7 ± 8.0 103.5 ± 11.2 <0.001
FFM (%) 79.1 ± 6.2 65.0 ± 7.7 <0.001
SBP (mmHg) 114.0 ± 6.6 136.0 ± 11.8 <0.001
DBP (mmHg) 68.1 ± 7.2 78.0 ± 8.3 <0.001
MBP (mmHg) 83.4 ± 5.9 97.4 ± 8.5 <0.001
·
VO2peak (mL·kg−1·min−1) 48.0 ± 8.2 22.4 ± 5.4 <0.001
CRP (mg/L) 0.8 ± 0.7 4.1 ± 3.9 <0.001
AST (U/L) 21.9 ± 3.6 25.1 ± 9.4 0.001
ALT (U/L) 18.1 ± 5.9 33.3 ± 21.2 <0.001
GGT (U/L) 16.7 ± 8.3 40.1 ± 41.9 <0.001
TC (mg/dL) 180.9 ± 35.8 206.5 ± 38.3 0.001
HDL-C (mg/dL) 63.0 ± 10.8 47.2 ± 11.0 <0.001
LDL-C (mg/dL) 104.8 ± 30.3 132.0 ± 34.1 <0.001
TG (mg/dL) 70.6 ± 21.3 139.6 ± 78.9 <0.001
TC/HDL-C 2.9 ± 0.5 4.6 ± 1.5 <0.001
Glucose (mg/dL) 83.1 ± 9.3 101.9 ± 24.4 <0.001
Insulin (mU/L) 3.9 ± 1.3 12.3 ± 7.3 <0.001
HOMA-IR 0.8 ± 0.4 3.3 ± 2.4 <0.001
HbA1c (%) 5.5 ± 0.3 5.9 ± 0.8 0.019
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Table 1. Cont.
Variables
HEALTHY EXERDIET-HTA P
PHEALTHY-EXERDIET-HTA(n = 31) (n = 219)
Medication Intake and Smoking Status
Statin (%) 0.0 14.2 0.024
Hypoglycaemic (%) 0.0 7.8 0.105
ACEI (%) 0.0 38.4 <0.001
ARB (%) 0.0 39.3 <0.001
Diuretic (%) 0.0 38.8 <0.001
CCB (%) 0.0 14.2 0.024
BB (%) 0.0 6.8 0.129
Antiplatelet (%) 0.0 3.7 0.275
Smokers (%) 15.6 11.0 0.533
BMI: Body mass index. FFM: Fat-free mass SBP: Systolic blood pressure. DBP: Diastolic blood pressure. MBP: Mean
blood pressure.
·
VO2peak: Peak oxygen consumption. CRP: C-reactive protein. AST: Aspartate aminotransferase.
ALT: Alanine transaminase. GGT: Gamma-glutamyl transpeptidase. TC: Total cholesterol. HDL-C: High-density
lipoprotein cholesterol. LDL-C: Low-density lipoprotein cholesterol. TG: Triglycerides. HOMA-IR: HOmeostatic
Model Assessment-Insulin resistance index. HbA1c: haemoglobin A1c. ACEI: Angiotensin-converting-enzyme
inhibitors. ARB: Angiotensin II receptor blockers. CCB: Calcium channel blockers. BB: Beta-blockers.
3.1. PRE versus POST Changes
Table 2 presents metabolic profile data at PRE, POST, and after 6 M follow-up. Analysing the
change in group from PRE to POST, a one-way repeated measures ANOVA found that the SupExT group
reduced concentrations of CRP (mean difference, ∆ = −1.5 mg/L, 95% confidence interval (CI) = −2.4,
−0.5 mg/L), ALT (∆ = −9.1 U/L, 95% CI = −14.3, −3.8 U/L), GGT (∆ = −9.1 U/L, 95% CI = −12.1,
−5.4 U/L), TC (∆ = −13.9 mg/dL, 95% CI = −20.4, −7.4 mg/dL), LDL-C (∆ = −9.5 mg/dL, 95% CI = −15.5,
−3.4 mg/dL), TG (∆ = −20.9 mg/dL, 95% CI = −30.3, −11.6 Mg/dL), TC/HDL-C (∆ = −0.3, 95% CI = −0.5,
−0.1), glucose (∆ = −6.7 mg/dL, 95% CI = −12.0, −1.5 mg/dL), insulin (∆ = −2.2 mU/L, 95% CI = −3.9,
−0.4 mU/L), HOMA-IR (∆ = −0.9, 95% CI = −1.5, −0.3), and HbA1C (∆ = −0.2%, 95% CI = −0.4, −0.1%).
The AC group had reduced concentrations of CRP (∆ = −1.0, 95% CI = −1.8, −0.1), while there was
no change in any other biochemical variable. Although the analysis by group found that the SupExT
group had a greater reduction than the AC group, there was no interaction of time by group for PRE
versus POST. Considering biochemical profile at POST, and the results previously presented for BMI,
BP, and CRF [11], at POST, participants in the present study were considered MHO (i.e., overweight
with healthy values of TC, TG, HDL-C, TC/HDL-C, glucose, insulin, HOMA, CRP, lower BP, and higher
CRF compared to PRE).
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Table 2. Changes in metabolic panel at pre-intervention (PRE), immediately post-intervention (POST), and 6 months post supervised exercise cessation (6 M).
Variables
All Effect AC ExT
Time × Group p Groups
PRE-POST
p Groups
POST-6 M
p Groups
PRE-6 M(n = 177) Size (ηp2) (n = 43) (n = 134)
CRP (mg/L)
PRE 4.0 ± 3.9 * 0.113 3.2 ± 3.2 * 4.1 ± 4.0 * 0.595 0.677 0.937 0.361
POST 2.6 ± 2.6 2.2 ± 2.1 2.7 ± 2.7
6 M 2.9 ± 3.0 ϕ 2.7 ± 2.5 3.0 ± 3.1 ϕ
AST (U/L)
PRE 24.7 ± 8.6 * 0.060 25.2 ± 5.8 24.6 ± 9.2 0.465 0.684 0.380 0.657
POST 22.6 ± 8.5 $ 21.3 ± 5.0 22.9 ± 9.2 $
6 M 25.0 ± 11.3 23.9 ± 6.2 25.3 ± 12.3
ALT (U/L)
PRE 33.4 ± 20.8 * 0.112 29.4 ± 12.8 34.4 ± 22.3 * 0.529 0.090 0.103 0.923
POST 25.1 ± 15.4 24.2 ± 14.7 25.3 ± 15.7
6 M 27.9 ± 20.4 27.3 ± 13.6 28.1 ± 21.9 ϕ
GGT (U/L)
PRE 36.1 ± 24.1 * 0.155 36.2 ± 24.8 36.1 ± 24.1 * 0.230 0.914 0.152 0.459
POST 27.4 ± 18.4 $ 28.9 ± 27.6 $ 27.0 ± 15.5 $
6 M 31.8 ± 20.6 37.1 ± 33.5 30.4 ± 15.9 ϕ
TC (mg/dL)
PRE 209.2 ± 36.3 * 0.103 207.3 ± 35.7 209.7 ± 36.6 * 0.281 0.102 0.330 0.195
POST 197.1 ± 35.4 $ 202.1 ± 35.9 $ 195.8 ± 35.2 $
6 M 207.8 ± 36.1 211.0 ± 39.7 206.9 ± 35.2
HDL-C (mg/dL)
PRE 48.6 ± 11.0 0.090 47.7 ± 8.0 48.8 ± 11.7 0.419 0.177 0.421 0.615
POST 48.5 ± 11.2 $ 47.1 ± 7.9 48.9 ± 12.0 $
6 M 51.0 ± 12.7 ϕ 48.8 ± 8.6 51.6 ± 13.6 ϕ
LDL-C (mg/dL)
PRE 135.2 ± 33.5 * 0.056 133.8 ± 35.4 135.6 ± 33.1 * 0.228 0.566 0.889 0.121
POST 127.3 ± 31.6 $ 131.2 ± 33.4 $ 126.2 ± 31.1 $
6 M 134.8 ± 31.5 140.4 ± 36.0 133.3 ± 30.1
TG (mg/dL)
PRE 125.2 ± 49.8 * 0.092 121.1 ± 38.2 126.3 ± 52.6 * 0.081 0.790 0.111 0.420
POST 108.2 ± 44.3 118.5 ± 45.4 105.4 ± 43.8
6 M 109.8 ± 43.2 ϕ 108.9 ± 41.8 110.0 ± 43.7 ϕ
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Table 2. Cont.
Variables
All Effect AC ExT
Time × Group p Groups
PRE-POST
p Groups
POST-6 M
p Groups
PRE-6 M(n = 177) Size (ηp2) (n = 43) (n = 134)
TC/HDL-C
PRE 4.6 ± 1.6 * 0.050 4.5 ± 1.1 4.5 ± 1.2 * 0.130 0.723 0.588 0.609
POST 4.3 ± 1.2 4.4 ± 1.2 4.2 ± 1.2
6 M 4.4 ± 1.2 ϕ 4.5 ± 1.1 4.2 ± 1.0 ϕ
Glucose (mg/dL)
PRE 102.3 ± 25.7 * 0.043 96.9 ± 12.6 104.0 ± 28.3 * 0.392 0.098 0.137 0.765
POST 96.8 ± 22.5 $ 95.2 ± 11.4 97.2 ± 24.9 $
6 M 101.1 ± 29.7 97.1 ± 16.0 102.3 ± 32.7
Insulin (mU/L)
PRE 11.5 ± 6.1 * 0.077 10.6 ± 5.5 11.8 ± 6.3 * 0.492 0.576 0.679 0.827
POST 9.6 ± 6.0 9.5 ± 5.0 9.6 ± 6.3
6 M 10.3 ± 5.9 9.3 ± 5.3 10.6 ± 6.1
HOMA-IR
PRE 3.1 ± 2.3 * 0.094 2.5 ± 1.3 3.3 ± 2.5 * 0.250 0.183 0.882 0.836
POST 2.3 ± 1.7 $ 2.2 ± 1.1 2.4 ± 1.8 $
6 M 2.8 ± 2.3 2.2 ± 1.5 3.0 ± 2.5
HbA1c (%)
PRE 5.9 ± 0.9 * 0.056 5.7 ± 0.3 6.0 ± 1.0 * 0.279 0.207 0.225 0.890
POST 5.7 ± 0.7 $ 5.6 ± 0.3 5.8 ± 0.7 $
6 M 5.9 ± 1.0 5.6 ± 0.4 5.9 ± 1.1
AC: attention control group. ExT: Exercise training group. CRP: C-reactive protein. AST: Aspartate aminotransferase. ALT: Alanine transaminase. GGT: Gamma-glutamyl transpeptidase.
TC: Total cholesterol. HDL-C: High density lipoprotein cholesterol. LDL-C: Low density lipoprotein cholesterol. TG: Triglycerides. HOMA-IR: HOmeostatic Model Assessment-Insulin
resistance index. HbA1c: Haemoglobin A1c. * p < 0.005 intra-group PRE versus POST. $ p < 0.005 intra-group POST versus 6 M. ϕ p < 0.005 intra-group PRE versus 6 M.
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3.2. POST versus 6-Month Follow-up Changes
A one-way repeated measures ANOVA found that between POST and 6 M follow-up in the
SupExT group, AST (∆ = 2.4 U/L, 95% CI = 0.1, 4.7 U/L), GGT (∆ = 3.5 U/L, 95% CI = 0.1, 6.9 U/L),
TC (∆ = 11.1 mg/dL, 95% CI = 4.4, 17.8 mg/dL), HDL-C (∆ = 2.8 mg/dL, 95% CI = 1.1, 4.4 mg/dL),
LDL-C (∆ = 7.1 mg/dL, 95% CI = 1.2, 13.0 mg/dL), glucose (∆ = 5.0 mg/dL, 95% CI = 0.6, 9.4 mg/dL),
HOMA-IR (∆ = 0.6, 95% CI = 0.1, 1.1), and HbA1C (∆ = 0.2%, 95% CI = 0.1, 0.3%) concentrations all
significantly increased. There were no significant changes in all other biochemical markers. In the
AC group, GGT (∆ = 8.2 U/L, 95% CI = 0.2, 16.2 U/L), TC (∆ = 8.9 mg/dL, 95% CI = 0.8, 17.0 mg/dL),
and LDL-C (∆ = 9.2 mg/dL, 95% CI = 0.6, 17.7 mg/dL) were significantly raised from POST to 6 M
follow-up. However, the two-way repeated measures ANOVA did not show an interaction of time by
group for POST versus 6 M follow-up. Considering biochemical profile at 6 M follow-up, participants
were again classified as MUO due to the following cardiometabolic abnormalities: obesity, higher
values of TC, LDL-C, glucose, BP, and lower CRF compared to POST [14].
3.3. PRE versus 6-Month Follow-up Changes
Analysing the change from PRE to 6 M follow-up for the groups, a one-way repeated measures
ANOVA found that, at 6 M follow-up, the SupExT group significantly reduced concentrations of CRP
(∆ = −1.2 mg/L, 95% CI = −2.2, −0.2 mg/L), ALT (∆ = −6.3 U/L, 95% CI = −12.6, −0.1 U/L), GGT
(∆ = −5.6 U/L, 95% CI = −11.1, −0.3 U/L), TG (∆ = −16.3 mg/dL, 95% CI = −26.4, −6.2 mg/dL), and
TC/HDL-C (∆ = −0.3, 95% CI = −0.5, −0.1), and raised values in HDL-C (∆ = 2.8 mg/dL, 95% CI = 1.3,
4.4 mg/dL). No significant changes were found in any variable in the AC group. As changes occurred
between PRE versus POST and POST versus 6 M follow up, no interaction of time by group was found
for changes in PRE versus 6 M follow-up.
3.4. Medication Intake
Regarding medication intake, 89% of SupExT participants and 88% of AC participants were taking
at least one medication at PRE. In SupExT, this percentage was significantly reduced in POST (83%,
p < 0.05) and in 6 M follow-up (79%, p < 0.001). Although there was a reduction between POST and 6 M
follow-up, the differences were not significant. In AC, 85.7% of participants were taking medication at
POST, but the reduction was not significant from PRE (p > 0.05). There was no change from POST to
6 M follow-up (85.7%). From SupExT participants, 25.2% reduced the dose of their medication from
PRE to POST, and 5.5% from POST to 6 M. Meanwhile, for the AC, 10.0% reduced the dose of their
medication from PRE to POST, with no change from POST to 6 M follow-up. In particular, changes in
SupExT medication intake were observed for statins (PRE 16.6%, POST 13.8%, 6 M follow-up 13.1%),
Angiotensin-converting-enzyme inhibitors (ACEIs) (PRE 34.5%, POST 30.3%, 6 M follow-up 27.6%),
and diuretics (PRE 42.1%, POST 37.9%, 6 M follow-up 36.6%). In AC, changes were only observed
in ACEIs (PRE 49.0%, POST 42.9%, 6 M follow-up 42.9%). No significant change was observed in
other medications. Although the separate analysis by group found more changes in SupExT than
in the AC, the chi-square test revealed that there were no significant between-group differences in
medication reduction. The percentage of smokers remained the same at PRE, POST, and 6 M follow-up
in both groups.
4. Discussion
The current study demonstrated that a 16-week SupExT intervention with hypocaloric diet
significantly improved cardiometabolic profiles from MUO to MHO. However, this was a transient
stage as after 6 M of no supervision, participants’ biochemical profiles and CRF had returned to MUO.
There is now increasing evidence that obese individuals with a healthy lifestyle pattern could have
a similar cardiovascular risk as healthy individuals with no obesity, since adherence to exercise and
healthy diet together lead to beneficial changes in body composition and cardiometabolic profile [32].
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The present study showed that the MUO profile in the EXERDIET-HTA group (i.e., obesity, HTN, fasting
glucose > 100 mg/dL, LDL-C > 100 mg/dL, TC > 200 mg/dL, ALT > 30 U/L, systemic inflammation
with CRP > 3 mg/L, and low CRF, 22.4 ± 5.4 mL·kg−1·min−1, Figure 2) was significantly worse than the
HEALTHY non-obese group (Table 1). These results confirm that obesity and physical inactivity are
the major contributing factors to dyslipidaemia manifested by elevated LDL-C and TG [33], inducing
chronic inflammation and activation of the renin angiotensin system, and exacerbating, consequently,
the sympathetic activation and BP [3].
The changes observed after conducting the 16-week exercise and diet intervention revealed that
the significantly better body composition and CRF (results published in previous papers) [11,14] may
be associated with a metabolic protective effect which improves insulin sensitivity, lipid panel, and
BP (Table 2, Figure 2). Thus, the whole sample significantly decreased their CRP (∆ = −1.4 mg/L)
concentrations (i.e., inflammatory marker associated with cardiovascular disease) which could be
explained by multiple mechanisms, including a decrease in cytokine production by adipose tissue,
skeletal muscles, endothelial and blood mononuclear cells, improved insulin sensitivity and endothelial
function, and possibly an antioxidant effect [34]. Interestingly, after the 16-week intervention, only
the SupExT group showed significant and beneficial changes in all variables, except HDL-C (Table 2).
Thus, lower concentrations of hepatic enzymes ALT (∆ = −9.1 U/L) and GGT (∆ = −9.1 U/L) were
shown, which in elevated concentrations are both highly related to liver and abdominal fat, and
predictors of the MUO phenotype, the diagnosis of non-alcoholic fatty liver disease, type 2 diabetes,
and subclinical atherosclerosis [35]. Previously, exercise and hypocaloric diet interventions have been
shown to improve hepatic lipid composition via different pathways [36]. Thus, some studies suggest
that exercise could modulate liver fat by directly altering hepatic lipid oxidation and lipogenesis [37],
and that the improvement may be driven by adiponectin and insulin sensitivity [38]. As such, this
may in part explain some of the beneficial changes seen in Table 2 after the 16-week intervention,
including: lower concentrations of glucose (∆ = −6.8 mmol/L), insulin (∆ = −2.2 mU/L), HOMA-IR
(∆ = −0.9 %), and HbA1C (∆ = −0.2 %). These markers have previously been shown to be some of the
chronic exercise adaptations seen in skeletal muscle after the upregulation of muscle GLUT4 protein,
increased enzyme capacities, and muscle capillarisation [39]. Similar to previous studies investigating
the beneficial effects of SupExT [33,40], the current study found that lipid profile improved with
lower concentrations of TC (∆ = −13.9 mmol/L), LDL-C (∆ = −9.4 mmol/L), TG (∆ = −20.9 mmol/L),
and TC/HDL-C (∆ = −0.3) at POST. Conversely, in the current study, HDL-C concentrations (upper
normal values at baseline) did not change after the exercise intervention. In other studies, which
included just SupExT with no diet intervention, it was common to find elevated concentrations of
HDL-C [15,33,41,42]. One possible explanation for this could be the incorporation of the DASH diet
in the current study. The DASH diet has been previously revealed to lower HDL-C concentrations,
along with TC, LDL-C [43,44], and TG [45]. The effect of the hypocaloric DASH diet in the intervention
must be considered, since it has been indicated that it is also effective at changing the biochemical
profile, i.e., lowering concentrations of CRP, AST, ALT, insulin, and HOMA-IR [45–47]. Further, the
benefits produced by SupExT are notable in CRF and body composition data (published data for the
same EXERDIET-HTA sample show greater benefits in SupExT compared to AC) [11,14]. Given the
strong association of CRF with metabolic risk [48], there appears to be a strong rationale for including
the CRF level in the prognosis of MHO to improve the stratification in individuals with obesity [5],
empowering the fat-but-fit paradigm and SupExT [49].
Although the aforementioned results show the benefits that aerobic exercise could add to the
hypocaloric DASH diet with respect to the biochemical profile (i.e., lower concentrations of glucose,
insulin, HOMA-IR, LDL-C, TC, TG, ALT, GGT, CRP), in the present study, when the ANCOVA analysis
was performed, no differences in the delta score (p > 0.05) were found between AC and SupExT for
any variables. However, considering that AC had fewer participants (n = 43) than SupExT (n = 134),
this lack of significance may have been due to power and thus, more research is needed to confirm or
deny this.
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Based on findings from the current study and that previously presented by the research team [11,14],
the 16-week intervention was effective in changing the metabolic profile from MUO to MHO according
to the following criteria (Figure 2) [7]: from obesity to overweight lowering body fat, with TC, ALT,
glucose, and CRP moving from unhealthy to optimal cut-off values, reflecting the absence of metabolic
abnormalities and lower levels of systemic inflammatory mediators, and CRF from “percentile under
50” to “percentile upper 50” for
·
VO2peak classification [29]. Further, participants reduced their BP
values (−5.4% reduction in MBP), and more than 7% of the participants stopped taking the medication
and 25% reduced their doses under medical supervision [11,14].
Although there was a significant improvement in the metabolic profile after the 16-week
intervention in the current study, there was subsequently a significant decline after 6 M when
supervision was removed (Table 2, Figure 2). The MHO panel at POST was unable to be maintained
after 6 M and participants regressed to MUO (Figure 2). The decrease in the lipidic, glycaemic,
and haemodynamic profiles found after 6 M of no supervision in the present study is consistent
with other studies which used different populations and with alternate types of exercise, duration
of intervention, and non-supervised time [36,41,42,50]. These negative effects may be secondary to
detraining-induced gains in body fat, favouring a more inflammatory status, and decreased CRF,
as observed in participants. Previous studies have shown the pathophysiology of obesity related
HTN [2]. Thus, an increase in the waist-to-hip ratio, parallel to a higher level of insulin, leptin, and
the renin-angiotensin-aldosterone system seems to stimulate the sympathetic nervous system and
concomitant increases in BP [2]. Further, it has already been established that a lower CRF, promoted
by detraining, enhances the risk of suffering from metabolic syndrome and detrimental effects to
the cardiovascular system, such as lack of regulation in BP, heart rate variability, myocardial oxygen
demand, endothelial function, and systemic inflammation, in conjunction with inefficient fat storage [7].
Hence, it seems clear that the physical activity level differs between MHO and MUO in adults [1,5].
This suggests that supervision or alternative strategies of exercise provision are required given the
need for MHO profile not to be a transient condition toward metabolic deterioration and consequently,
a higher risk of developing cardiovascular disease [51,52]. Thus, in the present study, although
the adherence with the 16-week intervention was very high in the SupExT, 6 M later, only 51%
of all participants were engaged in physical activity ( >2 times per week) and implementing the
recommendations (unpublished data from the EXERDIET-HTA study). However, it is interesting to
note that HDL-C concentrations were better at 6 M follow-up than in PRE (∆ = 2.4 mmol/L) and POST
(∆ = 2.5 mmol/L). This may be due to the effects of a non-supervised diet being a prominent factor in
HDL-C change, as previously discussed with the DASH diet [43,44].
In order to interpret findings from the current study, it is essential to consider both the strengths
and limitations. Since pre-intervention measurements, 23 individuals did not finish the intervention
and 19 participants did not attend the 6 M follow-up measurements, making the sample smaller, which
may have affected the between-group differences. Further, although medication intake and smoking
status was noted, it is difficult to assess the possible influence this had on the results. Dietary intake
was self-reported through questionnaires at PRE and POST, but it was not assessed at 6 M follow-up,
precluding knowledge about the adherence to the DASH diet.
Future areas for research could determine whether exercise and diet supervision can maintain
the achieved improvements in cardiometabolic health, by comparing 6 M with supervision and
without supervision. Further, it would be interesting to understand the reasons for the deterioration of
cardiometabolic health when the supervision is removed. Lastly, analysing the physical activity and
diet during the unsupervised period may provide information about the time course of these changes.
5. Conclusions
In conclusion, a 16-week SupExT and diet intervention was effective for improving cardiometabolic
panel from MUO to MHO in a non-physically active population with obesity and HTN. However,
this was a transient stage as after 6 M follow-up, participants returned to MUO. The findings of
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this study highlight the need for regular, systematic, and supervised diet and SupExT programs
to avoid subsequent declines in cardiometabolic health in people who are physically inactive with
overweight/obesity and HTN.
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